EMA Withdrawn: Forcaltonin (recombinant salmon calcitonin) — Unigene UK Ltd.

View source ↗

Summary

Forcaltonin (recombinant salmon calcitonin) has been withdrawn from the EMA; previously indicated for hypercalcemia, osteitis deformans, and bone resorption dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Resorption Disorders
• Hypercalcemia
• Osteitis Deformans

Drugs mentioned

• Forcaltonin (recombinant salmon calcitonin)

Snippet

Status: Withdrawn. Therapeutic area: Hypercalcemia;Osteitis Deformans;Bone Resorption. MAH: Unigene UK Ltd.. Decision date: 20/11/2008